212 related articles for article (PubMed ID: 12805124)
1. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors.
Gveric D; Herrera B; Petzold A; Lawrence DA; Cuzner ML
Brain; 2003 Jul; 126(Pt 7):1590-8. PubMed ID: 12805124
[TBL] [Abstract][Full Text] [Related]
2. The fibrinolytic system: A new target for treatment of depression with psychedelics.
Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S
Med Hypotheses; 2017 Mar; 100():46-53. PubMed ID: 28236848
[TBL] [Abstract][Full Text] [Related]
3. tPA receptors and the fibrinolytic response in multiple sclerosis lesions.
Gveric D; Herrera BM; Cuzner ML
Am J Pathol; 2005 Apr; 166(4):1143-51. PubMed ID: 15793294
[TBL] [Abstract][Full Text] [Related]
4. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
5. The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1.
Thelwell C; Longstaff C
J Thromb Haemost; 2007 Apr; 5(4):804-11. PubMed ID: 17408411
[TBL] [Abstract][Full Text] [Related]
6. Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.
Wun TC; Capuano A
Blood; 1987 May; 69(5):1354-62. PubMed ID: 3105619
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
Gveric D; Hanemaaijer R; Newcombe J; van Lent NA; Sier CF; Cuzner ML
Brain; 2001 Oct; 124(Pt 10):1978-88. PubMed ID: 11571216
[TBL] [Abstract][Full Text] [Related]
8. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.
Akassoglou K; Kombrinck KW; Degen JL; Strickland S
J Cell Biol; 2000 May; 149(5):1157-66. PubMed ID: 10831618
[TBL] [Abstract][Full Text] [Related]
9. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis as a Causative Mechanism for Bleeding Complications on Extracorporeal Membrane Oxygenation: A Pilot Observational Prospective Study.
Helms J; Curtiaud A; Severac F; Tschirhart M; Merdji H; Bourdin M; Contant G; Depasse F; Abou Rjeily R; Sattler L; Meziani F; Angles-Cano E
Anesthesiology; 2024 Jul; 141(1):75-86. PubMed ID: 38502917
[TBL] [Abstract][Full Text] [Related]
11. [Effect of fibrinogen, fibrin and fibrin (ogen) degradation products on the tissue plasminogen activator and plasminogen activator inhibitor-1 expressions of vascular endothelial cells in coculture system].
Cao YJ; Wu YH; Liu CF
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Jan; 36(1):62-7. PubMed ID: 19099932
[TBL] [Abstract][Full Text] [Related]
12. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease.
Kwieciński J; Josefsson E; Jin T
Inflamm Res; 2011 Nov; 60(11):1021-9. PubMed ID: 21786185
[TBL] [Abstract][Full Text] [Related]
14. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
Watanabe R; Wada H; Miura Y; Murata Y; Watanabe Y; Sakakura M; Okugawa Y; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Shiku H; Nobori T
Clin Appl Thromb Hemost; 2001 Jul; 7(3):229-33. PubMed ID: 11441985
[TBL] [Abstract][Full Text] [Related]
16. Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation.
East E; Gverić D; Baker D; Pryce G; Lijnen HR; Cuzner ML
Neuropathol Appl Neurobiol; 2008 Apr; 34(2):216-30. PubMed ID: 17983428
[TBL] [Abstract][Full Text] [Related]
17. Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi.
Whyte CS; Mostefai HA; Baeten KM; Lucking AJ; Newby DE; Booth NA; Mutch NJ
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672724
[TBL] [Abstract][Full Text] [Related]
18. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
19. Compartmentalized Actions of the Plasminogen Activator Inhibitors, PAI-1 and Nsp, in Ischemic Stroke.
Torrente D; Su EJ; Fredriksson L; Warnock M; Bushart D; Mann KM; Emal CD; Lawrence DA
Transl Stroke Res; 2022 Oct; 13(5):801-815. PubMed ID: 35122213
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
